This is a phase II single arm trial to evaluate the objective response rate of abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
SponsorsThis trial is sponsored by National Cancer Institute (NCI).
Interested in Clinical Trial?
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Professor of Interdisciplinary Clinical Oncology
- Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology
- Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistResidency Program Director for Obstetrics and Gynecology; Leader of Cancer Control and Prevention; Professor of Interdisciplinary Clinical Oncology
- Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology